Global Ovarian Cancer Market 2014-2018 is a new market research publication announced by Reportstack. Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological cancers worldwide and a leading cause of death. Ovarian cancer is difficult to diagnose in the initial stages because the symptoms are similar to that of gastric disorders like bloating, abdominal discomfort, difficulty in eating in the early stage and nausea, vomiting, constipation and diarrhoea in the later stages. It is often diagnosed in advanced stages when the metastasis has set in because the diagnostic techniques are not well-developed. Ovarian cancer can be treated by using chemotherapy, targeted therapy, and surgery. Although the market has a limited number of drugs for the treatment of ovarian cancer currently, a strong product pipeline is in development for the forecast period.
The analysts forecast the Global Ovarian Cancer market will grow at a CAGR of 13.85 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Ovarian Cancer market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ovarian cancer that are available in the market. The report Global Ovarian Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Ovarian Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The analysts forecast the Global Ovarian Cancer market will grow at a CAGR of 13.85 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Ovarian Cancer market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ovarian cancer that are available in the market. The report Global Ovarian Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Ovarian Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
• Americas
• EMEA
• APAC
Key Vendors
• Bristol Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc
• Janssen Pharmaceuticals Inc.
• F. Hoffman-La Roche Ltd
• Bristol Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc
• Janssen Pharmaceuticals Inc.
• F. Hoffman-La Roche Ltd
Other Prominent Vendors
• Aprea AB
• Aetera Zenteris Inc.
• Amgen Inc.
• Astra Zeneca plc
• Bionumerik Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• Genentech Inc.
• MEI Pharmaceuticals Inc.
• Nektar Therapeutics
• NeoPharm Inc.
• Novogen Inc.
• Oasmia Pharmaceuticals AB
• Synta Pharmaceuticals Corp.
• Aprea AB
• Aetera Zenteris Inc.
• Amgen Inc.
• Astra Zeneca plc
• Bionumerik Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• Genentech Inc.
• MEI Pharmaceuticals Inc.
• Nektar Therapeutics
• NeoPharm Inc.
• Novogen Inc.
• Oasmia Pharmaceuticals AB
• Synta Pharmaceuticals Corp.
Key Market Driver
• Promising Drug Pipeline.
• For a full, detailed list, view our report.
• Promising Drug Pipeline.
• For a full, detailed list, view our report.
Key Market Challenge
• Lack of Accurate Diagnosis of Ovarian Cancer.
• For a full, detailed list, view our report.
• Lack of Accurate Diagnosis of Ovarian Cancer.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in the Funding Activities.
• For a full, detailed list, view our report.
• Increase in the Funding Activities.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Companies Mentioned
Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., F. Hoffman-La Roche Ltd, Aprea AB, Aetera Zenteris Inc., Amgen Inc., Astra Zeneca plc, Bionumerik Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Genentech Inc., MEI Pharmaceuticals Inc., Nektar Therapeutics, NeoPharm Inc., Novogen Inc., Oasmia Pharmaceuticals AB, Synta Pharmaceuticals Corp.
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Companies Mentioned
Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., F. Hoffman-La Roche Ltd, Aprea AB, Aetera Zenteris Inc., Amgen Inc., Astra Zeneca plc, Bionumerik Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Genentech Inc., MEI Pharmaceuticals Inc., Nektar Therapeutics, NeoPharm Inc., Novogen Inc., Oasmia Pharmaceuticals AB, Synta Pharmaceuticals Corp.
To view the table of contents and know more details please visit Global Ovarian Cancer Market 2014-2018.
No comments:
Post a Comment